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We report the analyses of breakpoints in 31 phenotypically normal and 14 abnormal carriers of balanced translocations. Our study
assesses the differences between balanced translocations in normal carriers and those in abnormal carriers, focusing on the presence
of genomic imbalances at the breakpoints or elsewhere in the genome, presence of cryptic chromosome rearrangements, and gene
disruption. Our hypothesis is that all four features will be associated with phenotypic abnormalities and absent or much less frequent
in a normal population. In the normal cohort, we identiﬁed neither genomic imbalances at the breakpoints or elsewhere in the genome
nor cryptic chromosome rearrangements. In contrast, we identiﬁed candidate disease-causing imbalances in 4/14 abnormal patients.
These were three breakpoint associated deletions and three deletions unrelated to the breakpoints. All six de novo deletions originated
on the paternally inherited chromosome. Additional complexity was also present in one of these cases. Gene disruption by the break-
points was present in 16/31 phenotypically normal individuals and in 5/14 phenotypically abnormal patients. Our results show that
translocations in phenotypically abnormal patients aremolecularly distinct from those in normal individuals: the former aremore likely
to be associated with genomic imbalances at the breakpoints or elsewhere and with chromosomal complexity, whereas the frequency of
gene disruption is similar in both normal and abnormal translocation carriers.Introduction
Apparentlybalancedreciprocal translocationsareacommon
type of chromosome rearrangement found both in patients
with phenotypic abnormalities and in clinically unaffected
individuals.Most rearrangements are inherited, but approx-
imately one in ﬁve is a de novo event.1 These de novo rear-
rangements represent a challenge in prenatal genetic coun-
seling, given that the risk of an abnormal phenotype is
quoted as ~6.1%.2 The study of such rearrangements might
provide an understanding of the molecular features that ac-
count for the abnormal phenotypes observed. First, reports
of such studies have shown the presence of cryptic imbal-
ances at or near the breakpoint regions in a proportion of pa-
tientswithabnormalphenotypes.Kumaretal.3 foundbreak-
point-associated deletions in 2/3 patients, and Wirth et al.4
reported deletions in 2/6 patients presenting with mental
retardation. These reports have been followed by others
that show that a proportion of apparently balanced rear-
rangements are in fact unbalanced.5–10 Second, imbalances
unrelated to the breakpoint regions have been reported by
Gribble et al.,9 who applied array CGH to the study of ten
phenotypically abnormal carriers of apparently balanced
translocations and found3/10 tohave imbalances in regions
not involved in the translocations. In a similar study,DeGre-
gori et al.10 found 4/27 phenotypically abnormal carriers of
apparentlybalanced reciprocal translocations tohave imbal-
ances unrelated to the breakpoints. Although these imbal-Theances couldbe causal to the abnormalphenotypes, the inter-
pretation of such cases is complicated by the presence of an
abnormal karyotype. Third, apparently balanced transloca-
tions in phenotypically abnormal carriers have been shown,
in some cases, to be complex chromosome rearrange-
ments.8–14 Complex rearrangements have at least three
breakpoints and involve two or more chromosomes, and it
can be assumed that the probability of an abnormal pheno-
type increases with the number of breakpoints involved.15
Fourth, the direct breakpoint-mediated disruption of the ex-
pression pattern of dosage-sensitive genes can also account
for phenotypic abnormalities,16–22 as can breakpoint-medi-
ated disruption of regulatory regions by position effect.23
These ﬁndings have established the value of the molecular
characterization of breakpoints for the discovery of disease-
causative genes and historically have led to the unraveling
of the genetic cause of several Mendelian disorders.24
In contrast to the reports on phenotypically abnormal
translocation carriers, molecular studies of phenotypically
normal carriers have not been conducted systematically
and are mainly undertaken in the context of familial stud-
ies in order to aid the interpretation of chromosome rear-
rangements found in phenotypically abnormal patients.
We previously reported amolecular study of 13 normal car-
riers of balanced translocations in which we detected nei-
ther cryptic chromosomal complexity nor imbalances at
the breakpoints or unrelated to the breakpoints. However,
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further evaluate the signiﬁcance of our original observa-
tions, we have analyzed 18 additional individuals and
extended the molecular analyses of the 13 previously
reported individuals. We obtained detailed clinical infor-
mation on all 18 additional cases to gauge the signiﬁcance
of our ﬁndings.
In thepresent study,weaimed todetermine the frequency
of the aforementioned four features in 31 phenotypically
normal individuals with balanced rearrangements, using
ﬂuorescence in situ hybridization (FISH) and 1 Mb array
CGH, and to compare the results to those of a cohort of 14
phenotypically abnormal carriers of apparently balanced re-
arrangements analyzed by array painting, FISH, and array
CGH with the Sanger 30K Whole Genome Tilepath clone
set (WGTP) platform.Our ﬁndingswill contribute to the de-
termination of the differences between balanced rearrange-
ments in phenotypically normal individuals from those in
phenotypically abnormal patients, which will be of value
in a diagnostic setting, particularly in the interpretation of
de novo rearrangements diagnosed prenatally.
Subjects and Methods
Subjects
(1) Phenotypically Normal Study Population
This study included individuals presenting with what was
assumed to be a clinically normal phenotype who were found to
be carriers of a de novo apparently balanced reciprocal transloca-
tion following referral for cytogenetic analysis. Individuals were
classiﬁed as having a normal phenotype if no clinical abnormali-
ties were mentioned in the original referral and if the reason for
referral included recurrent miscarriages or routine diagnostic test-
ing for family members of known carriers of cytogenetic abnor-
malities. Individuals meeting these criteria were selected from
the Salisbury Treasury of Interesting Chromosomes (STOIC),
which contains records, dating from 1967 to the present, on all
cytogenetic abnormalities diagnosed at the Wessex Regional
Genetics Laboratory. Ethical approval for this study was given by
a Multi-center Research Ethics Committee (UK). A blood sample
was obtained by a clinical geneticist, genomic DNA was extracted,
and PHA-stimulated cultures were prepared. Additionally, lym-
phoblastoid cell lines (LCLs) were established by Epstein-Barr virus
transformation according to standard procedures and stored for
future investigations. We also carried out further analyses in the
13 individuals previously reported25 and from whom detailed
clinical information is not available. A summary of the karyotypes
and mode of ascertainment is given in Table 1.
(2) Phenotypically Abnormal Study Population
This study included 14 patients with a clinically abnormal pheno-
type who were found by conventional microscopy to have an
apparently balanced chromosome rearrangement. All patients
had conﬁrmed de novo rearrangements, except for case 50, of
which the maternal karyotype was normal but a paternal sample
was unavailable. Peripheral blood samples were collected from
the patients and their parents after fully informed consent was
obtained, and genomic DNA- and PHA-stimulated cultures were
prepared from the blood samples. In addition, LCLs were estab-
lished from each patient. Karyotypes of all patients and their
modes of ascertainment are given in Table 2.928 The American Journal of Human Genetics 82, 927–936, April 20(3) Genotype-Phenotype Correlations
A detailed medical examination by a clinical geneticist (C.M.) was
carried out, and this phenotypic information is presented in
Tables S1 and S2. Patient examination was performed without
prior knowledge of the molecular ﬁndings. The molecular results
were subsequently collated with the clinical information in an
attempt to establish genotype-phenotype correlations, and a reex-
amination of the patient was undertaken when necessary. Details
of the translocation breakpoints and array-cgh results have been
added to the DECIPHER database and will appear in Ensembl
when consent for this has been speciﬁcally obtained.
Methods
Normal Cohort
Breakpoint Mapping Studies. FISH studies were carried out by stan-
dard methods, with probes derived from BACs (Bacterial Artiﬁcial
Chromosomes) or PACs (P1-derived Artiﬁcial Chromosomes)map-
ped to the bands of the cytogenetically assigned breakpoints and
selected from the EnsemblHumanGenomeBrowser. The gene con-
tent of the breakpoint regions was determined with the Ensembl
and theUCSCgenomebrowsers based onNCBI Build 36. For break-
points located in regions harboring genes, further ﬁne mapping
was undertaken by FISH with fosmid clones or by array-painting
analysis26 with fosmid clones and customized PCR products.
Array CGH. Array CGH experiments were conducted via the
Sanger 1Mb array platform, as described by Fiegler et al.27 Patients’
genomic DNA samples were competitively hybridized with a refer-
ence DNA from multiple donors (Promega) in a sex-mismatch
experiment. The results were analyzed with the BlueFuse for mi-
croarrays software (BlueGnome, UK). Copy-number gains and
losses were called manually for replicate clones showing a log2
ratio of 50.5. Results were compared to data from studies on
normal subjects recorded in the database of genomic variants
(DGV) and in the human genome browsers Ensembl and UCSC.
Abnormal Cohort
Whole-genome array-CGH studies were performed with the
Sanger 30K Whole Genome TilePath (WGTP) arrays as described
by Fiegler et al.28 Brieﬂy, genomic patient- and reference-DNA
samples were differentially labeled and hybridized to the arrays
in duplicate via dye-reversal experiments. Custom Perl scripts
were used to combine the dye-swap results and to detect regions
of copy-number changes. All copy-number changes observed
were compared to copy-number variants (CNVs) reported in previ-
ous studies of normal populations and available from the database
of genomic variants (DGV) and the Ensembl and ucsc browsers.
Regions not previously reported as CNVs and including at least
two clones were singled out for further investigations, which
included conﬁrmatory studies by FISH and parent-of-origin analy-
sis by microsatellite analysis with genomic DNA samples from the
proband and each parent according to standard methods. Table 3
lists the markers used.
Array Painting. The rearrangement breakpoints were mapped by
array painting, as described by Fiegler et al.26 Derivative chromo-
somes were ﬂow sorted from LCLs and ampliﬁed via DOP PCR
or via the GenomePlex Complete Whole Genome Ampliﬁcation
kit (Sigma). The derivative chromosomes from each rearrange-
ment were differentially labeled in Cy3 and Cy5 and hybridized
onto Sanger 30K WGTP arrays. Data analysis was undertaken
with the BlueFuse for microarrays software (BlueGnome, UK),
and the array-painting results were conﬁrmed by FISH.
FISH Experiments. Large-insert clones in target regions were
selected from the Ensembl browser. FISH experiments were08
Table 1. Karyotypes and Mode of Ascertainment of the Normal Study Population
Case1 Karyotype Ascertainment Previous Description
1A 46,XY,t(2;14)(p21;q13)de novo Parent of a 46,XX,t(2;14)(p21;q13) miscarriage
1B 46,XX,t(3;9)(p26.2;p22.3)de novo Parent of a 46,XY,add(3)(p25.3) clinically
affected child
1C 46,X,t(X;7)(?q27;q22)de novo Parent of a 46,X,Xqþ clinically affected child
1D 46,XX,t(10;18)(q24.3;q12.2)mat Relative of 46,XY,t(10;18)(q24.3;q12.2) ascertained
prenatally because of high serum screen risk
case 12 in Baptista et al.(2005)
2A 46,XX,t(4;16)(q35.1;p13.13)de novo Parent of a clinically affected child presenting a rea(4)
2B 46,XX,t(1;13)(q32.3;q32.3)de novo Parent of a 46,XY,13qþ clinically affected child
2C 46,XY,t(2;18)(q35;q21.3)de novo Recurrent miscarriages
2D 46,XX,t(2;9)(q21.3;p13)de novo Parent of a 46,XX,t(2;9)(q21.3;p13) amniocentesis
because of advanced maternal age
2E 46,XX,t(7;17)(q36.1;q25.1)de novo Recurrent miscarriages
2F 46,XY,t(8;15)(p11.2;q24)de novo Parent of a 46,XY,t(8;15)(p11.2;q24) amniocentesis
because of advanced maternal age
2G 46,XY,t(1;13)(p22;q32)de novo Parent of a 46,XY,t(1;13)(p22;q32) clinically affected child
2H 46,XY,t(11;21)(p15.4;p12)de novo Parent of a clinically affected child presenting a paternal
dup(11)
2I 46,XX,t(2;7)(p23.3;p22.3)de novo Prenatal for advanced maternal age case 1 in Baptista et al.(2005)
2J 46,XX,t(11;17)(p13;p13.1)mat Parent of a 46,XY,t(11;17)(p13;p13.1) clinically affected
child
case 2 in Baptista et al.(2005)
2K 46,XX,t(7;16)(p15;q22)mat Recurrent miscarriages case 4 in Baptista et al.(2005)
2L 46,XY,t(8;16)(q22.1;q13)pat Sibling of a 46,XX,t(8;16) (q22.1;q13) girl ascertained
because of delayed puberty
case 5 in Baptista et al.(2005)
2M 46,XX,t(16;18)(q24;q21.1)mat Recurrent miscarriages case 7 in Baptista et al.(2005)
2N 46,XX,t(5;18)(p13;q11)pat Relative of 46,XX,t(5;18)(p13;q11)pat amniocentesis
because of family history of Down syndrome.
case 9 in Baptista et al.(2005)
2O 46,XY,t(1;11)(q42.3;q21)pat Parent of 46,XX, t(1;11)(q42.3;q21) amniocentesis
because of family history of Down syndrome.
case 10 in Baptista et al.(2005)
2P 46,XX,t(3;10)(p23;q21.2)pat Relative of a 46,XY,t(3;10)(p23;q21.2) clinically affected
child
case 11 in Baptista et al.(2005)
3A 46,XX,t(4;6)(q27;p25)de novo Recurrent miscarriages
3B 46,XX,t(8;12)(p23.1;p13.1)de novo Parent of a 46,XY, add(8)(p23.1) clinically affected child
3C 46,XX,t(6;9)(q22.2;p22.3)de novo Recurrent miscarriages
3D 46,XY,t(2;4)(p23;p12)de novo Recurrent miscarriages
3E 46,X,t(X;22)(p11.23;q13.1)de novo Parent of a 46,X,t(X;22)(p11.23;q13.1) amnio because of
family history of Down syndrome
3F 46,XX,t(11;15)(q23;q22)de novo Parent of a 46,XY,t(11;15)(q23;q22) amnio because of
advanced maternal age
3G 46,XX,t(2;6)(q32.2;p23)de novo Recurrent miscarriages
3H 46,XX,t(6;22)(p21.3;q13)pat Parent of a 46,XX,del(15)(q11q12) clinically affected child case 3 in Baptista et al.(2005)
3I 46,XX,t(1;19)(q42.13;p13.2)mat Recurrent miscarriages case 6 in Baptista et al.(2005)
3J 46,XX,t(9;20)(p24.1;p11.2?3)mat Parent of a 46,XY,der(9)t(9;20)(p24.1;p11.2?3) clinically
affected child
case 8 in Baptista et al.(2005)
3K 46,XY,t(2;3)(p23.1;q29)mat Relative of a 46,XX,der(3)t(2;3)(p23.1;q29) clinically affected
child
case 13 in Baptista et al.(2005)
1 Prefix 1 refers to cases with no genes at the breakpoints. Prefix 2 indicates cases with obligatory breakpoint-mediated gene disruption. Prefix 3 refers to
cases with potential breakpoint-mediated gene disruption.undertaken on cell suspensions in 3:1 methanol:acetic acid pre-
pared either from LCLs or from peripheral blood samples accord-
ing to standard methods. The gene content of regions of interest
was determined with the Ensembl browser and/or the UCSC
browsers based on NCBI build 36. For regions containing putative
candidate genes, further reﬁning of the breakpoints was under-
taken with fosmid clones selected from the UCSC browser.
Results
We present the results ﬁrst for the clinically normal cohort
and second for the clinically abnormal cohort. For each
cohort, we consider the four features that are the focus ofThethis study; namely, breakpoint-associated imbalances,
genomic imbalances unrelated to the breakpoints, addi-
tional chromosomal complexity, and gene disruption.
Phenotypically Normal Cohort
(1) FISH Investigation of the Presence of Imbalances
at the Breakpoint Regions
We initially characterized the breakpoint regions by FISH
with BAC- or PAC-derived probes (resolution of ~150 kb),
and for a subset of breakpoints found to map in the vicin-
ity of genes we conducted higher-resolution mapping with
fosmid clones (resolution of ~40 kb) or PCR products (res-
olution up to ~10 kb). At this level of resolution, none ofAmerican Journal of Human Genetics 82, 927–936, April 2008 929
Table 2. Karyotypes and Mode of Ascertainment of the Abnormal Study Population
Case Karyotype Ascertainment
16 46,XX,t(10;22)(q24.3;q13.31)dn DD, epilepsy
20 46,XX,t(2;5)(q33;q12)dn DD, mild mental retardation
43 46,XY,t(4;17)(q35.1;q25.1)dn Truncus arteriosus, NAA
45 46,X,t(X;19)(q21;p13.11)dn Premature ovarian failure, NAA
48 46,XY,t(4;6)(q33;q22.2)dn DD, dysmorphic features
49 46,XX,t(2;10)(q33;q21.2)dn DD, cleft palate, behavioral abnormalities
50 46,X,t(X;8)(q22.1;q24.13)nk Premature ovarian failure, NAA
51 47,XX,t(4;20)(p15.2;p11.23)dn,þmar mat DD, autistic spectrum disorder
52 46,XX inv ins (11;4)(q22.2;q13.2q21.3)dn DD, LD, short stature, scoliosis
53 46,XX,t(4;8)(q21.1;p12)dn DD, regressive skills
54 46,XY,t(14;15)(q23;q26.3)dn dysmorphic features, coarctation of aorta
55 46,XY,t(19;20)(q13.43;q11.1)dn Severe oligospermia, NAA
56 46,XY,t(6;21)(q16.2;q11.2)dn Severe oligospermia, NAA
57 46,XY,t(2;5)(p23;q11.2)dn,t(18;22)(q11.2;p13)dn DD, short stature, macrocephaly, epilepsy
DD denotes developmental delay.
LD denotes learning difficulties.
NAA denotes no additional abnormalities.
nk denotes parental origin unknown.the breakpoint regions analyzed were associated with
deletions or duplications of DNA segments.
(2) Whole-Genome Analysis by Array CGH
Using array CGH at 1 Mb resolution we identiﬁed an aver-
age of 8.4 regions of copy number change in each genome
studied. All regions of imbalance found in this normal
cohort were totally or partially overlapping with regions
previously reported as harbouring normal CNVs docu-
mented in the DGV, UCSC and Ensembl browsers.
(3) Assessment of the Presence of Cryptic Chromosomal
Complexity
Using FISH analysis, we observed that all the translocations
analyzed involvedonlytwochromosomeswithamaximum
of two breakpoints per rearrangement, a ﬁnding that is
consistent with the absence of chromosomal complexity
in the rearrangements studied. However, for case 3H,
46,XX,t(6;22)(p21.3;q13)pat, we found that the break-
point-mapping results were inconsistent with the assembly
order of the fosmid clones used. This was because the fos-
mid WI2-1419L13, which mapped centromeric to the
breakpoint-spanning fosmid (WI2-2878H11), did not hy-
bridize to chromosome 22 and derivative 22 as expected,
but instead hybridized to chromosome 22 and derivative
6. This could be explained by the presence of a small inver-
sionat thebreakpoint, butwewereunable todetermine this
byFISHdue to thecloseproximityof these fosmids.Alterna-
Table 3. Microsatellites Selected for Parental-Origin Studies
Case Chromosome Markers
20 5q12.1-q12.3 D5S1474, D5S76, D5S1718, D5S427,
D5S1956, D5S1359
52 4q13.3 D4S2641, D4S2389
52 4q21.23 D4S1534, D4S2691
53 4q13.3-q21.1 D4S3249, D4S2958, D4S1558
53 10p14 D10S1649, D10S465
57 4q32.1 D4S3016, D4S1556, D4S1498930 The American Journal of Human Genetics 82, 927–936, April 20tive explanations for this result are an error in the assembly
or an error in the assigned identity of the clones used.
(4) Analysis of the Gene Content at the Breakpoint Regions
Table 4 details the breakpoint-mapping results. Based on
the status of gene disruption by the breakpoints, we have
subdivided the individuals into three groups: 1, 2, and 3.
In group 1, no knowngenesweremapped to the breakpoint
regions. In group 2, for at least one of the translocation
breakpoints, the breakpoint region was fully mapped
within a gene and consequently caused interruption of
the sequence of that gene. Because we have not carried
out gene-function analysis, we refer to gene disruption
when the sequence of a gene is interrupted by a breakpoint
and acknowledge that the interruption of a gene’s sequence
might not always correlate with impairment of its function
caused by complex gene-expression-regulatory mecha-
nisms in humans. Individuals in group 3 had potential
gene disruption by at least one of the breakpoints due to
the presence of a gene(s) in part of the breakpoint-contain-
ing region. We present estimates of the likelihood of gene
disruption based on the gene size within the total area of
the breakpoint-containing interval. This measurement of-
fers a good indication of the probability of gene disruption,
although a more accurate estimate would need to take into
accountnotonly the sizebut also the relativepositionof the
gene(s) within the breakpoint region. In summary, Table 4
shows that 16 breakpoints mapped to regions containing
no known genes, 18 were fully contained within a gene,
and 23 were mapped to an interval partly occupied by
a gene. The remaining three breakpointsmapped to regions
for which Ensembl and UCSC showed gene-mapping
discrepancies.
Phenotypically Abnormal Cohort
The results of array-CGH analysis are summarized in Table
5, and full details of the breakpoint-mapping results are
given in Table 6.08
(1) Rearrangements with Breakpoint-Associated Imbalances
Case 20: 46,XX,t(2;5)(q33;q12)de novo. This patient had
a 2.5 Mb deletion at the 5q breakpoint that encompasses
6 known genes (Table S3). FISH studies showed the dele-
tion to be de novo and microsatellite analysis showed
that it originated on the paternal chromosome.
Case 53: 46,XX,t(4;8)(q21.1;p12)de novo. This patient had
a 2.1 Mb deletion at the 4q breakpoint, which encom-
passes 21 known genes (Table S3). Microsatellite analysis
showed this to be a de novo deletion of paternal origin.
In addition, array CGH identiﬁed a 1.1 Mb deletion
on 10p14, which encompasses the predicted gene
LOC389936 (unknown function). This was found by
microsatellite analysis to be de novo and paternal in origin.
(2) Rearrangements with Genomic Imbalances Unrelated
to the Breakpoints
Case 50: 46,X,t(X;8)(q22.1;q24.13). This patient had a bal-
anced translocation, but array CGH identiﬁed a ~200 kb
deletion on 2p13.2. This deletion included part of the
EXOC6B (exocyst complex component 6B) gene and was
shown by FISH to be present in the patient’s phenotypi-
cally normal mother. This deletion is therefore likely to
be an example of a novel asymptomatic CNV, but it is in-
cluded here because it has not been reported previously.
Case 57: 46,XY,t(2;5)(p23;q11.2)de novo, t(18;22)
(q11.2;p13)de novo. This patient had two independent
balanced translocations. In addition, array CGH identiﬁed
a 2Mb deletion unrelated to the translocations, on 4q32.1,
which encompasses nine known genes (Table S3). Micro-
satellite analysis showed this deletion to have occurred
de novo on the paternally derived chromosome.
(3) Rearrangements with Additional Chromosomal Complexity
Case 52: 46,XX inv ins (11;4)(q22.2;q13.2q21.3)de novo. This
patient had a ~170 kb deletion at the 4q21.23 breakpoint,
which contains no known genes. In addition, array CGH
identiﬁed a 1.8 Mb deletion ~8.4 Mb distal to the 4q13.1
translocation breakpoint and ~12 Mb proximal to the
4q21.23 breakpoint. This encompasses six known genes
(Table S3). Both deletions were conﬁrmed by FISH to
have a de novo origin, and microsatellite marker analysis
showed that these originated on the paternal chromosome.
In addition, FISH results near the 4q21.23 breakpoint were
consistent with a potential inversion at this location.
(4) Analysis of the Gene Content in Rearrangements
with no Detected Chromosomal Imbalance
The remaining rearrangements in this study were all found
to be balanced translocations with no genomic imbalances
detected (other than reported CNVs). We further analyzed
the gene content of the breakpoint-containing regions in
these cases. Table 6 shows that eight breakpoints mapped
to regions containing no known genes, whereas ﬁve were
deﬁnitely associated with gene disruption and eleven
were potentially associated with gene disruption. Two
other breakpoints mapped to regions for which Ensembl
and UCSC showed gene-mapping discrepancies. The
remaining two breakpoints were mapped to regions con-
taining genes which were deleted.TheDiscussion
Imbalances at the Translocation Breakpoints
We have analyzed 31 translocations in phenotypically
normal carriers and have not identiﬁed any breakpoint-
associated imbalances. In contrast, three of the 14 clini-
cally abnormal patients had a breakpoint-associated
imbalance. All the imbalances were de novo deletions of
170 kb to 2.5 Mb, and all had arisen on the paternal chro-
mosome. These ﬁndings provide further evidence that
genomic imbalances are an important cause of phenotypic
abnormalities in carriers of apparently balanced rearrange-
ments.3–11,29
Genomic Imbalances Unrelated to the Breakpoints
We have detected genomic imbalances unrelated to the
breakpoints in all of the 31 normal individuals, but these
were previously reported CNVs. In contrast, when we ap-
plied tiling-path array CGH to the 14 patients in the abnor-
mal cohort we found previously reported CNVs in all pa-
tients, and four patients also had previously unreported
deletions unrelated to the breakpoints. The deletions in
cases 52, 53, and 57 were de novo with origins on the pa-
ternally derived chromosomes, whereas case 50 had a ma-
ternally inherited deletion, representing a novel CNV. Ge-
nomic imbalances unrelated to the breakpoints have also
been reported in other studies,9,10 and the increasing utili-
zation of array CGH will help deﬁne the overall frequency
of such imbalances. Furthermore, these observations have
important implications for the establishment of genotype-
phenotype correlations because they imply that the contri-
bution of novel unbalanced regions independent of the
breakpoints needs to be considered. For example, Hayashi
et al.30 described a 1 Mb de novo deletion at 1q25 in a girl
with Cornelia de Lange syndrome [MIM 122470] and
a t(5;13)(p13.1;q12.1), and it appeared that both the
deletion and the disruption of the NIPBL [MIM 608677]
gene by the 5p translocation breakpoint contributed to
the phenotype.
Additional Chromosomal Complexity in Apparently
Balanced Rearrangements
Patsalis et al.13 reported cryptic chromosomal complexity
in 3/20 phenotypically abnormal balanced translocation
carriers analyzed by FISH. In other studies, with FISH
and/or array CGH, cryptic chromosomal complexity was
uncovered in 4/4 patients,11 in 3/10 patients,9 and in
5/27 patients10 with phenotypic abnormalities. In our
series, additional chromosomal complexity was not de-
tected in any of the normal individuals, and only one of
the clinically abnormal patients had a complex rearrange-
ment: case 52 had a rearrangement with three breakpoints,
which on further analysis was found to have a minimum
of six breakpoints.American Journal of Human Genetics 82, 927–936, April 2008 931
Table 4. Summary of the Breakpoint-Mapping Results in the Normal Cohort
Case BCI Genomic Position
Size of the
BCI (bps) Gene Content within the BCI
Likelihood of Gene
Disruption1
1A chr2:42,992,855-43,173,584 180,729 — —
chr14:40,212,036-40,381,064 169,028 — —
1B chr3:581,645-958,276 376,631 — —
chr9:11,302,383-11,764,217 461,834 — —
1C chrX:148,867,102-149,050,276 183,174 — —
chr7:108,572,249-108,768,779 196,530 — —
1D chr10:110,225,647-110,411,173 185,526 — —
chr18:37,199,353-37,363,565 164,212 — —
2A chr4:187,776,924-187,818,201 41,277 FAT 100
chr16:8,687,646-8,767,351 79,705 ABAT 100
2B chr1:206,420,427-206,463,044 42,617 PLXNA2 100
chr13:95,145,761-95,229,198 83,437 DNAJC3 100
2C chr2:214,463,710-214,641,904 178,194 SPAG16 100
chr18:53,150,966-53,228,407 77,441 ST8SIA3 15
2D chr2:138,955,571-139,047,575 92,004 SPOPL 75
chr9:35,316,944-35,352,859 35,915 UNC13B 100
2E chr7:132,668,430-132,886,439 218,009 EXOC4 100
chr17:53,768,215-53,854,109 85,894 RNF43 80
2F chr8:42,400,367-42,558,693 158,326 SLC20A2, C8orf40 80
chr15:71,562,896-71,677,866 114,970 NPTN, LOC283677 100
2G chr1:101,729,637-101,888,180 158,543 — —
chr13:91,284,473-91,451,991 167,518 GPC5 100
2H chr11:8,789,238-8,828,410 39,172 ST5 70-100
chr21: satellite stalk nd nd nd
2I chr2:36,974,205-36,984,164 9,959 STRN 100
chr7:11,125,470-11,131,360 5,890 PHF14 100
2J chr11:37,799,191-37,800,372 1,181 — —
chr17:12,739,251-12,759,331 20,080 QRICH2 100
2K chr7:24,352,315-24,556,482 204,167 — —
chr16:68,412,623-68,499,123 86,500 WWP2 100
2L chr8:100,008,198-100,013,461 5,263 STK3 0-100
chr16:59,138187-59,146,748 8,561 — —
2M chr16:82,997,304-83,005,803 8,499 ATP2C2 100
chr18:42,902,560-42,915,062 12,502 HDHD2 100
2N chr5:38,450,546-38,489,171 38,625 EGFLAM 100
chr18:16,935,079-16,977,780 42,701 ROCK1 25
2O chr1:235,542,200-235,725,748 183,548 RYR2 100
chr11:98,312,650-98,487,722 175,072 CNTN5 0-50
2P chr3:25,187,406-25,225,486 38,080 — —
chr10:71,325,230-71,369,369 44,139 COL13A1 100
3A chr4:125,648,232-125,829,198 180,966 ANKRD50 15
chr6:7,324,263-7,409,496 85,233 CAGE1, RIOK1 45
3B chr8:6,719,131-7,053,466 334,335 DEFB1, DEFA6, DEFA4, DEFA1, DEFA3, DEFA5 10
chr12:7,987,953-8,310,582 322,629 Q9UCR6, FOXJ2, C3AR, NECAP1, CLEC4A,
Q9BZV8, ZNF705A, Q4G0H1, FAM90A1
25-75
3C chr6:119,215,818-119,302,998 87,180 C6orf61, ASF1, MCM9 40-65
chr9:14,904,963-15,184,142 279,179 C9orf52 10
3D chr2:26,218,578-26,257,187 38,609 FAM59B 20
chr4:48,429,074-48,516,206 87,132 FRYL 55
3E chrX:57,142,101-57,184,980 42,879 SPIN2B, SPIN2A 10
chr22:19,026,823-19,108,026 81,203 USP41, ZNF74 35-75
3F chr11:115,668,958-115,830,806 161,848 — —
chr15:48,315,253-48,399,500 84,247 HDC, GABPB2 75
3G chr2:200,490,832-200,529,742 38,910 FLJ38973, FLJ37953 95
chr6:6,601,851-6,706,437 104,586 — —
3H chr6:40,838,172-40,840,190 2,018 — —
chr22:30,870,135-30,908,432 38,297 LOC150297 25
3I chr1:223,565,344-223,691,038 125,694 LBR 20
chr19:13,999,383-14,039,028 39,645 RLN3, IL27RA 60
3J chr9:6,427,961-6,601,726 173,765 UHRF2, GLDC 85
chr20:23,000,436-23,041,115 40,679 CD93 15
3K chr2:27,620,439-27,812,447 192,008 C2orf16, ZNF512, CCDC121, XAB1,
SUPT7L, SLC4A1AP
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Table 5. Summary of the Array-CGH Results in the Abnormal Cohort
Case Breakpoint-Associated Imbalance (Genomic Position) Other Genomic Imbalance (Genomic Position)
20 del(5)(q12.1q12.3)de novo(61,052,997-63,598,644) —
50 — del(2)(p13.2p13.2)mat(72,376,684-72,574,196)
52 del(4)(q21.23q21.23)de novo(86,384,696-86,558,920) del(4)(q13.3q13.3)de novo(72,636,161-74,421,392)
53 del(4)(q13.3q21.1)de novo(74,932,950-77,060,297) del(10)(p14p14)de novo(8,423,513-9,583,339)
57 — del(4)(q32.1q32.1)de novo(156,373,857-158,388,330)Gene Disruption at the Breakpoints
Unexpectedly, we observed that in both the clinically nor-
mal and the abnormal cohorts, the great majority of the
breakpoints were located in the vicinity of genes (typically
within less than 200 kb, see Tables 4 and 6). Furthermore,
for breakpoint regions with no known genes (in both
cohorts), all but one mapped within 1.2 Mb of a gene, i.e.,
within the current maximum known range of position ef-
fects.31 In the normal cohort, 27% of the breakpoints map-
ped within regions that harbor no genes, 32% were associ-
ated with obligatory gene breakage, and the remaining
41% were associated with potential gene disruption. Simi-
larly, in the 14 phenotypically abnormal carriers, 33% of
the breakpoints located to regions containing no genes,
21% disrupted genes, and 46% were potentially associated
withgenedisruption.Theproportionof thehumangenome
occupied by annotated genes has been estimated as ~38.5%
(37.2%of introns and1.3%of exons)32 or ~34.8% (Ensembl
database version 46.36h). We observed that a minimum of
21% and a maximum of 70% of the breakpoints disrupt
genes. The lower ﬁgure of 21% iswithin the expected values
for a randomlocalizationofbreakpoints,whereas thehigher
ﬁgure of 70% suggests a preferential location of the break-
points to within genes. However, at the resolution of the
techniques used here we cannot draw further conclusions.
Genes Disrupted by the Breakpoints and Genotype-
Phenotype Correlations
We conducted extensive literature searches on all genes
mapped within breakpoint regions in both cohorts using
data from the GO database, OMIM, the Human Gene
Mutation database, UniProt, GeneCards, and the DGV.
Surprisingly, we found that genes implicated in transcrip-
tion and signal transduction were the most common types
of genes in the breakpoints of both cohorts. Themost strik-
ing difference between the cohorts was that genes with
a role in the nervous system were present in 5/14 (36%)
abnormal patients but in only 2/31 (6.5%) of the normal
individuals, suggesting that this type of gene is an impor-
tant cause of clinical abnormalities. Further analysis
showed that, in both cohorts, as many as 50% of the genes
mapped to the breakpoints were located in regions previ-Theously reported to have normal copy-number variation.
Moreover, many genes were largely uncharacterized, but
a minority have been implicated in phenotypic abnormal-
ities and are discussed below.
Gene Disruption in Phenotypically Normal
Individuals
Among the 31 phenotypically normal patients, we found
breakpoint-mediated disruption of 18 genes (Table 4). Of
these, RYR2 (ryanodine receptor 2 cardiac [MIM
180902]), FAT (FAT tumor-suppressor homolog 1, Drosoph-
ila [MIM 600976]), ABAT (4-aminobutyrate aminotransfer-
ase [MIM 137150]), and EXOC4 (exocyst complex compo-
nent 4) are of particular interest. Mutations in RYR2 (case
2O) are a cause of familial arrhythmogenic right-ventricu-
lar dysplasia 2 [MIM 600996] and of stress-induced
polymorphic ventricular tachycardia [MIM 604772]. Un-
fortunately, the clinical history of case 2O is unknown,
and therefore we are unable to establish genotype-pheno-
type correlations. Case 2A had disruption of both the
FAT and the ABAT genes. FAT encodes a tumor-suppressor
protein in Drosophila but is largely uncharacterized in
humans. Interestingly, case 2A developed a prolactinoma
at 37 years of age (Table S1), suggesting that further studies
would be of interest to ascertain whether FAT disruption
causes this type of tumor. Mutations in ABAT are associated
with GABA-AT deﬁciency [MIM 137150]. Case 2A did not
present any of the features of this autosomal-recessive dis-
order, which is consistent with the presence of a normal
functioning allele on the nontranslocated chromosome.
Finally, EXOC4 was disrupted in case 2E. Disruption of
this gene and the formation of a truncated protein have
been previously reported in a patient with microcephaly,
developmental delay, and a t(7;10)(q33;q23) de novo.29
Gene Disruption in Phenotypically Abnormal
Individuals
Among the clinically abnormal patients, we have attemp-
ted to identify disease-candidate genes at the breakpoint
regions. For case 49, we identiﬁed disruption of the
SATB2 (SATB homeobox 2 [MIM 608148]) gene. Haploin-
sufﬁciency of SATB2 is known to cause cleft palate,18 andBCI denotes breakpoint-containing interval.
nd denotes not determined.
1 The probability of gene disruption (as a percentage) was calculated as the physical size of a given gene in relation to the size of the breakpoint-con-
taining interval. Two estimates are given in the cases in which gene-mapping discrepancies were found between the Ensembl and the UCSC genome
browsers (these are due to the use of different algorithms for gene annotation).American Journal of Human Genetics 82, 927–936, April 2008 933
Table 6. Summary of the Breakpoint-Mapping Results in the Abnormal Cohort
Case BCI Genomic Position Size of the BCI (bps) Gene Content within the BCI Likelihood of Gene Disruption1
16 chr10:102,470,424-102,509,479 39,055 PAX2 40
16 chr22:42,975,258-43,015,630 40,372 KIAA1644 100
20 chr2:203,884,002-203,963,572 79,570 ABI2 80
20 chr5:60,919,174-61,052,997 nd associated with a deletion nd
43 chr4:181,557,356-181,712,629 155,273 — —
43 chr17:62,750,206-62,824,693 74,487 PSMD12, PITPNC1 60
45 chrX:78,833,496-78,996,054 162,558 — —
45 chr19: centromeric nd nd nd
48 chr4:172,112,115-172,314,669 202,554 — —
48 chr6:111,251,547-111,344,802 93,255 AMD1 23
49 chr2:199,874,411-199,911,683 37,272 SATB2 100
49 chr10:64,314,352-64,495,348 180,996 — —
50 chrX:115,042,292-115,233,384 191,092 AGTR2 3
50 chr8:142,582,086-142,790,550 208,464 — —
51 chr4:17,806,803-18,134,168 327,365 — —
51 chr20:10,200,284-10,241,852 41,568 SNAP25 85
52 chr4:64,164,472-64,348,036 183,564 — —
52 chr4:87,196,675-87,397,572 200,897 MAPK10 100
52 chr11:99,613,168-99,929,275 316,107 CNTN5 40
53 chr4:74,827,036-75,000,632 nd associated with a deletion nd
53 chr8:35,542,879-35,705,808 162,929 UNC5D 100
54 chr14:55,276,675-55,382,178 105,503 Q6NVV1_HUMAN 0-2
54 chr15:94,659,356-94,695,383 36,027 NR2F2, AK000872 30-65
55 chr19:63,177,283-63,220,873 43,590 ZNF606, Q8N9G5_HUMAN 70
55 chr20:28,033,231-28,197,751 164,520 Q6ZS48_HUMAN 0-5
56 chr6:97,826,527-97,908,737 82,210 C6orf167, AK091365 14-68
56 chr21: centromeric nd nd nd
57 chr2:24,640,005-24,682,052 42,047 NCOA1 50
57 chr5:57,413,898-57,782,197 368,299 — —
57 chr18:20,893,727-21,067,881 174,154 ZNF521 100
57 chr22: satellite stalk nd nd nd
‘‘BCI’’ denotes ‘‘breakpoint-containing interval.’’
‘‘nd’’ denotes ‘‘not determined.’’
1 The probability of gene disruption (as a percentage) was calculated as the physical size of a given gene in relation to the size of the breakpoint-con-
taining interval. Two estimates are given in the cases in which gene-mapping discrepancies were found between the Ensembl and the UCSC genome
browsers (these are due to the use of different algorithms for gene annotation).thus SATB2 disruption must explain the presence of this
malformation in case 49. Case 51 had potential disruption
of the SNAP25 (synaptosomal-associated protein, 25kDa
[MIM 600322]) gene. This gene has a role in regulation
of neurotransmitter release, and it could be involved in
the synaptic function of speciﬁc neuronal systems. Fur-
thermore, polymorphisms of SNAP25 have been associated
with behavioral traits such as hyperactivity/impulsivity
and inattention,33 suggesting that SNAP25 is a good candi-
date for the Attention Deﬁcit Hyperactivity Disorder
(ADHD [MIM 143465]) in case 51. In case 48, AMD1
(adenosylmethionine decarboxylase 1 [MIM 180980])
was potentially disrupted. This gene encodes an intermedi-
ate enzyme involved in polyamine biosynthesis. Poly-
amines might be involved in brain development and
cognitive function,34 suggesting that AMD1 is a good can-
didate gene for the developmental delay in case 48. Case 54
had potential disruption of the NR2F2 (nuclear receptor
subfamily 2, group F, member 2 [MIM 107773]). Studies
in mice indicate that NR2F2 might be implicated in heart
defects,35 suggesting that this gene is a good candidate
for the cardiac abnormality in case 54.934 The American Journal of Human Genetics 82, 927–936, April 20In summary, in the phenotypically normal cohort we
have not identiﬁed (1) breakpoint-associated imbalances,
(2) genomic imbalances unrelated to the breakpoints, or
(3) chromosomal complexity. In contrast, in our pheno-
typically abnormal cohort, breakpoint-associated imbal-
ances, both at the breakpoints and elsewhere in the
genome, and chromosome complexity were present in
4/14 patients. These results, considered in combination
with those of our previously studied cohort,9 show that ge-
nomic imbalances detectable by array CGH could be the
underlying cause of phenotypic abnormalities in a signiﬁ-
cant proportion of patients with an apparently balanced
rearrangement. These observations agree with those re-
ported by De Gregori et al.10 Furthermore, it is of interest
that all but one of the de novo imbalances identiﬁed in
studies of apparently balanced rearrangements9–11 were
paternal in origin. This suggests that male gametogenesis
is particularly susceptible to the factor(s) responsible for
this class of chromosome abnormality.10
We identiﬁed gene disruption by the breakpoints in both
phenotypically normal and abnormal individuals, the pro-
portion being similar in both groups but with genes08
implicated in biological processes of the nervous system
being more frequent in the abnormal cohort. The presence
of a normal phenotype is consistent with the disruption of
genes that are not developmentally regulated dosage-sensi-
tive genes, whereas the presence of an abnormal pheno-
type suggests the interruption of putative disease genes,
which are good candidates for further study.
Supplemental Data
Supplemental Data include three tables and can be foundwith this
article online at http://www.ajhg.org/.
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